Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Pyelonephritis|Urinary Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2023-507117-10-00 | P1 |
Not yet recruiting |
Pyelonephritis|Urinary Tract Infections |
2024-01-16 |